Operator: Good afternoon, ladies and gentlemen, and welcome to the Vistagen Therapeutics Fiscal Year 2025 Second Quarter ...
On Monday, TG Therapeutics Inc common stock (TGTX) stock saw a modest uptick, ending the day at $30.74 which represents a slight increase of $1.93 or 6.70% from the prior close of $28.81. The stock ...
Q3 2024 Earnings Call Transcript November 4, 2024 TG Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...
TG Therapeutics ( (TGTX) ) has released its Q3 earnings. Here is a breakdown of the information TG Therapeutics presented to its investors. TG ...
Matthew Kaplan; Analyst; Ladenburg Thalmann & Co. Inc Mayank Mamtani; Analyst; B. Riley Securities ...
Opthea's lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with ...
Third quarter 2024 U.S. BRIUMVI net revenue of $83.3 millionRaises full year 2024 U.S. BRIUMVI net revenue target to $300 - $305 ...
The biopharmaceutical company posted revenue of $83.9 million in the period, which beat Street forecasts. Four analysts surveyed by Zacks expected $80.3 million. TG Therapeutics expects full-year ...
12d
AM ETNEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: TGTX), today announced that a conference call will be held, Monday November 4, 2024, at 8:30 AM ET to discuss results for the third quarter ...
We recently compiled a list of the 10 Stocks Set to Explode in 2025. In this article, we are going to take a look at where TG ...
P4L AI users benefit from in-platform diamonds, which they will soon be able to convert into $P4L tokens. This planned ...
On Tuesday, TD Cowen initiated coverage on shares of TG Therapeutics (NASDAQ:TGTX), assigning a Buy rating with a price target of $50.00. The firm's coverage is based on the potential of TG ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback